期刊
EJNMMI RESEARCH
卷 6, 期 -, 页码 -出版社
SPRINGER HEIDELBERG
DOI: 10.1186/s13550-016-0165-z
关键词
Cancer-targeting peptide; alpha 3 beta 1 integrin; One-bead one-compound combinatorial peptide library; Glioblastoma; Optical imaging
资金
- NIH [R21 CA135345, R01CA115483]
- University of California Cancer Research Coordinating Committee
Background: alpha 3 beta 1 integrin is overexpressed in several types of human cancer and is associated with poor prognosis, metastasis, and resistance to cancer treatment. We previously identified a cyclic peptide ligand LXY1 that specifically binds to the alpha 3 beta 1 integrin on human glioblastoma U-87MG cells. Here, we optimized LXY1 through one-bead one-compound combinatorial library screening and site-specific modifications to improve its in vivo binding property. Methods: Three bead libraries were synthesized and whole-cell binding assays were performed. The binding capacity of individual peptide ligands against different tumor cells was determined by flow cytometry and confirmed by optical imaging. A complex joining biotinylated ligand with streptavidin-Cy5.5 was used for in vivo target imaging in both subcutaneous and orthotopic U-87MG xenograft mouse models. Results: LXY30, a cyclic peptide with the sequence cdG-Phe(3,5-diF)-G-Hyp-NcR, emerged as the most potent and selective ligand for the alpha 3 subunit of alpha 3 beta 1 integrin with improved in vitro and in vivo tumor-targeting effects compared to LXY1 in U-87MG cells. LXY30 is considerably stable in plasma as demonstrated in an in vitro stability study in 90 % human plasma. LXY30 also binds to several other known alpha 3 beta 1 integrin-expressing glioblastoma, lung, and breast cancer cell lines with various affinities. Conclusions: Our data support further investigating the role of LXY30 as a human tumor-targeting peptide ligand for systemic and intracranial delivery of imaging agents and cancer therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据